Search results for "arco"

showing 10 items of 1716 documents

Synovial sarcoma and malignant mesothelioma of the pleura: Review, differential diagnosis and possible role of apoptosis

2001

Synovial sarcoma of the pleural cavity is exceptionally rare and may be confused, both clinically and histologically, with malignant mesothelioma, with subsequent inappropriate therapy. To address this dilemma, four biphasic synovial sarcomas (BSSs) and four biphasic malignant mesotheliomas (BMMs) were studied with a panel of mucin and immunohistochemical stains to determine if they would allow one to distinguish between the two. The BMMs were all pleural-based. The BSSs were extrapleural. The mucin and immunohistochemical stains were all performed on formalin-fixed, paraffin-embedded tissue using standard techniques, with appropriate positive and negative controls. Mucin present in BSS is,…

AdultMaleMesotheliomaPathologymedicine.medical_specialtyAdolescentPleural Neoplasms2734ApoptosisPathology and Forensic MedicineNeoplasms Multiple PrimarySynovial sarcomaSarcoma SynovialPleural diseaseBiomarkers TumormedicineHumansMesotheliomaMalignant mesotheliomaAgedAged 80 and overStaining and Labelingbusiness.industryMucinApoptosis; Immunohistochemistry; Malignant mesothelioma; Synovial sarcoma; 2734MucinsApoptosiMiddle AgedPeriodic Acid-Schiff ReactionPleural cavitymedicine.diseaseImmunohistochemistrySynovial sarcomamedicine.anatomical_structureFemaleAlcian BlueSarcomaNeoplasm Recurrence LocalDifferential diagnosisCalretininbusiness
researchProduct

Reducing Body Myopathy with Cytoplasmic Bodies and Rigid Spine Syndrome: A Mixed Congenital Myopathy

2001

At the age of five years a male child started to develop a progressive rigid spine, torsion scoliosis, and flexion contractures of his elbows, knees, hips, and ankles owing to severe proximal and distal muscle weakness. He had three muscle biopsies from three different muscles at ages 7, 11, and 14 years, respectively. Myopathologically, these muscle tissues contained numerous inclusions which, at the ultrastructural level, turned out to be reducing bodies and cytoplasmic bodies, often in close spatial proximity. Similar histological inclusions, although not further identified by histochemistry and electron microscopy, were seen in his maternal grandmother's biopsied muscle tissue who had d…

AdultMaleMuscle tissuePathologymedicine.medical_specialtyWeaknessScoliosisSpinal Muscular Atrophies of ChildhoodSarcomereMyositis Inclusion BodymedicineHumansGenetic Predisposition to DiseaseMuscle SkeletalMyopathyMyositisAgedInclusion Bodiesbusiness.industrySyndromeGeneral MedicineAnatomymedicine.diseasePenetrancePedigreemedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionLordosisFemaleDesminNeurology (clinical)medicine.symptombusinessMyopathies Structural CongenitalNeuropediatrics
researchProduct

Heart and Skeletal Muscles: Linked by Autonomic Nervous System.

2019

Background Resting sympathetic hyperactivity and impaired parasympathetic reactivation after exercise have been described in patients with heart failure (HF). However, the association of these autonomic changes in patients with HF and sarcopenia is unknown. Objective The aim of this study was to evaluate the impact of autonomic modulation on sarcopenia in male patients with HF. Methods We enrolled 116 male patients with HF and left ventricular ejection fraction < 40%. All patients underwent a maximal cardiopulmonary exercise testing. Maximal heart rate was recorded and delta heart rate recovery (∆HRR) was assessed at 1st and 2nd minutes after exercise. Muscle sympathetic nerve activity (MSN…

AdultMaleMuscleSkeletallcsh:Diseases of the circulatory (Cardiovascular) systemSarcopeniaSympathetic Nervous Systemheart failurelihaksetBioinformaticsAutonomic Nervous SystemsarcopeniaYoung AdultOxygen ConsumptionHeart Ratehomeostasisautonominen hermostomedicinemyocardiumHomeostasisHumansBlunted Vagal Reactivation.Muscle StrengthsydäntauditMuscle SkeletalAgedsympathetic nervous systemSympathetica Nervous SystemHeart FailureHand Strengthbusiness.industryMyocardiumautonomic nervous systemHeartMiddle Agedmedicine.diseaseAutonomic nervous systemSympathetic Hyperactivitylcsh:RC666-701Heart failureSarcopeniaExercise TestOriginal Articlemuscle skeletalShort EditorialCardiology and Cardiovascular Medicinebusinesshuman activitiesHomeostasislihasvoimaArquivos brasileiros de cardiologia
researchProduct

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study

2022

Abstract Background The opioid antagonist extended-release naltrexone (XR-NTX) in the treatment of opioid use disorder (OUD) is effective in terms of safety, abstinence from opioid use and retention in treatment. However, it is unclear how patients experience and adjust to losing the possibility of achieving an opioid effect. This qualitative study is the first to explore how people with opioid dependence experience XR-NTX treatment, focusing on the process of treatment over time. Methods Using a purposive sampling strategy, semi-structured interviews were undertaken with 19 persons with opioid use disorder (15 men, four women, 22–55 years of age) participating in a clinical trial of XR-NTX…

AdultMaleNarcotic AntagonistsGeneral MedicineMiddle AgedOpioid-Related DisordersInjections IntramuscularNaltrexoneAnalgesics OpioidYoung AdultVDP::Medisinske Fag: 700::Helsefag: 800Delayed-Action PreparationsHumansFemale
researchProduct

Measurement of end-tidal carbon dioxide in spontaneously breathing patients in the pre-hospital setting. A prospective evaluation of 350 patients

2002

Monitoring of end-tidal carbon dioxide (EtCO(2)) is good clinical practice in the patient who is intubated and ventilated. This study investigated the EtCO(2) values in spontaneously breathing patients treated in a physician-staffed mobile intensive care unit (MICU). This article also discusses whether EtCO(2) monitoring may have an influence on therapeutic decisions by emergency physicians by providing additional information.Over a period of 6 months, 350 spontaneously breathing patients (162 males, 137 females) were treated and transported in our MICU and monitored using a LifePak 12 monitor (EtCO(2), respiratory rate, pO(2), blood pressure, heart rate). Only 299 were enrolled in the stud…

AdultMaleNarcoticsArtificial ventilationEmergency Medical ServicesSubarachnoid hemorrhageAdolescentRespiratory ratemedicine.medical_treatmentAmbulancesEmergency Nursinglaw.inventionSeizureslawHumansMedicineProspective StudiesTidal volumeAgedAged 80 and overbusiness.industryGlasgow Coma ScaleCarbon DioxideMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseIntensive care unitAsthmaHypoglycemiaBlood pressureAnesthesiaEmergency MedicineBreathingFemaleCardiology and Cardiovascular MedicinebusinessResuscitation
researchProduct

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Factors influencing the opioid response in advanced cancer patients with pain followed at home: The effects of age and gender

2000

The aim of this study was to evaluate the influence of age and gender on pain characteristics and opioid response in advanced cancer patients followed at home. A perspective study was carried out in a sample of 181 consecutive advanced cancer patients who required opioids in the last 4 weeks before death. Pain intensity and symptoms associated with opioid therapy at weekly intervals for 4 weeks were recorded, as were the previous oncological treatments. Opioid doses increased over time, but remained stable in the last 2 weeks of life, while pain intensity decreased over time despite unchanged use of NSAIDs. A considerable increase in symptom intensity was observed in the last weeks of life,…

AdultMaleNarcoticsNauseaPain medicineOpioidSex FactorsAgeNeoplasmsmedicineHumansProspective StudiesCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalysis of VarianceTerminal Carebusiness.industryAge FactorsGenderVisceral painMiddle AgedHome Care ServicesPain IntractableProspective epidemiological studyOpioidOncologyAnesthesiaNeuropathic painVomitingFemalemedicine.symptomCancer painbusinessmedicine.drug
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

&lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct

Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated …

2015

Cancer cachexia is a syndrome characterized by weight loss (WL) and sarcopenia. Aim of the study was to assess the impact of cachexia on head and neck changes during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy in a series of locally advanced oropharyngeal cancer.Volume variations of sternocleidomastoid muscle (SCM) were considered as surrogate of muscle changes related to sarcopenia. Two head and neck diameters, encompassing the cranial limits of II and III nodal levels (defined as 'head diameter' and 'neck diameter', respectively), were measured. All parameters were defined retrospectively by means of on-board cone beam computed tomography images at 1-8…

AdultMaleOncologymedicine.medical_specialtyCachexiamedicine.medical_treatmentLocally advancedMedicine (miscellaneous)030218 nuclear medicine & medical imagingCachexia03 medical and health sciences0302 clinical medicineInternal medicineWeight LossCarcinomamedicineHumansskin and connective tissue diseasesAgedCisplatinNutrition and DieteticsArc (protein)business.industryMiddle Agedmedicine.diseaseRadiation therapyOropharyngeal NeoplasmsOropharyngeal Carcinoma030220 oncology & carcinogenesisSarcopeniaFemaleRadiotherapy Intensity-Modulatedsense organsRadiologyCisplatinbusinessHeadNeckmedicine.drugEuropean Journal of Clinical Nutrition
researchProduct